{"id":"apatinib","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Vascular endothelial growth factor receptor 2","category":"target"},{"label":"KDR","category":"gene"},{"label":"RET","category":"gene"},{"label":"KIT","category":"gene"},{"label":"Active","category":"status"},{"label":"Secondary malignant neoplasm of stomach","category":"indication"},{"label":"Zhongda Hospital","category":"company"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protein Kinase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":133.827,"date":"","count":34,"signal":"Palmar-plantar erythrodysaesthesia syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=134)"},{"llr":112.394,"date":"","count":30,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=112)"},{"llr":96.293,"date":"","count":26,"signal":"Proteinuria","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=96)"},{"llr":81.391,"date":"","count":25,"signal":"Bone marrow failure","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=81)"},{"llr":55.876,"date":"","count":8,"signal":"Secondary hypertension","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=56)"}],"commonSideEffects":[]},"trials":[],"aliases":["Apatinib mesylate","ATAN","apatinib tablets","YN968D1","AiTan"],"company":"Zhongda Hospital","patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:33:14.781996","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Apatinib","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:30:40.851163+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:30:47.353662+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Apatinib","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:30:47.543922+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3186534/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:30:48.390648+00:00"}},"allNames":"rivoceranib","offLabel":[],"synonyms":["rivoceranib","apatinib","apatinib mesylate","apatinib mesilate","YN968D1"],"timeline":[],"brandName":"Rivoceranib","ecosystem":[{"indication":"Secondary malignant neoplasm of stomach","otherDrugs":[{"name":"trastuzumab","slug":"trastuzumab","company":"Genentech"}],"globalPrevalence":null}],"mechanism":{"target":"Vascular endothelial growth factor receptor 2","targets":[{"gene":"KDR","source":"DrugCentral","target":"Vascular endothelial growth factor receptor 2","protein":"Vascular endothelial growth factor receptor 2"},{"gene":"RET","source":"DrugCentral","target":"Proto-oncogene tyrosine-protein kinase receptor Ret","protein":"Proto-oncogene tyrosine-protein kinase receptor Ret"},{"gene":"KIT","source":"DrugCentral","target":"Mast/stem cell growth factor receptor Kit","protein":"Mast/stem cell growth factor receptor Kit"},{"gene":"CSK","source":"DrugCentral","target":"Tyrosine-protein kinase CSK","protein":"Tyrosine-protein kinase CSK"},{"gene":"SRC","source":"DrugCentral","target":"Proto-oncogene tyrosine-protein kinase Src","protein":"Proto-oncogene tyrosine-protein kinase Src"},{"gene":"RIPK3","source":"DrugCentral","target":"Receptor-interacting serine/threonine-protein kinase 3","protein":"Receptor-interacting serine/threonine-protein kinase 3"},{"gene":"ZAK","source":"DrugCentral","target":"Mitogen-activated protein kinase kinase kinase MLT","protein":"Mitogen-activated protein kinase kinase kinase MLT"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Rivoceranib is a potent inhibitor of VEGFR2 tyrosine kinase, which is a key enzyme involved in the signaling pathway that regulates angiogenesis (the formation of new blood vessels). By inhibiting VEGFR2, Rivoceranib disrupts the tumor's ability to recruit new blood vessels, leading to reduced tumor growth and metastasis."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5211","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Apatinib","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Apatinib","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:44:27.003647","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:30:49.975969+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"axitinib","drugSlug":"axitinib","fdaApproval":"2012-01-27","patentExpiry":"Jun 14, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"bosutinib","drugSlug":"bosutinib","fdaApproval":"2012-09-04","patentExpiry":"Nov 23, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dabrafenib","drugSlug":"dabrafenib","fdaApproval":"2013-05-29","patentExpiry":"Oct 15, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"dasatinib","drugSlug":"dasatinib","fdaApproval":"2006-06-28","patentExpiry":"Sep 28, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"erlotinib","drugSlug":"erlotinib","fdaApproval":"2004-11-18","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"fedratinib","drugSlug":"fedratinib","fdaApproval":"2019-08-16","patentExpiry":"Sep 24, 2039","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"fostamatinib","drugSlug":"fostamatinib","fdaApproval":"2018-04-17","patentExpiry":"Sep 4, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"ibrutinib","drugSlug":"ibrutinib","fdaApproval":"2013-11-13","patentExpiry":"Sep 3, 2036","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"midostaurin","drugSlug":"midostaurin","fdaApproval":"2017-04-28","patentExpiry":"Oct 9, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"neratinib","drugSlug":"neratinib","fdaApproval":"2017-07-17","patentExpiry":"Oct 15, 2028","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"apatinib","indications":{"approved":[{"name":"Secondary malignant neoplasm of stomach","source":"DrugCentral","snomedId":94606003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(1516)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"axitinib","brandName":"axitinib","genericName":"axitinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"bosutinib","brandName":"bosutinib","genericName":"bosutinib","approvalYear":"2012","relationship":"same-target"},{"drugId":"dabrafenib","brandName":"dabrafenib","genericName":"dabrafenib","approvalYear":"2013","relationship":"same-target"},{"drugId":"dasatinib","brandName":"dasatinib","genericName":"dasatinib","approvalYear":"2006","relationship":"same-target"},{"drugId":"erlotinib","brandName":"erlotinib","genericName":"erlotinib","approvalYear":"2004","relationship":"same-target"},{"drugId":"fedratinib","brandName":"fedratinib","genericName":"fedratinib","approvalYear":"2019","relationship":"same-target"},{"drugId":"fostamatinib","brandName":"fostamatinib","genericName":"fostamatinib","approvalYear":"2018","relationship":"same-target"},{"drugId":"ibrutinib","brandName":"ibrutinib","genericName":"ibrutinib","approvalYear":"2013","relationship":"same-target"},{"drugId":"midostaurin","brandName":"midostaurin","genericName":"midostaurin","approvalYear":"2017","relationship":"same-target"},{"drugId":"neratinib","brandName":"neratinib","genericName":"neratinib","approvalYear":"2017","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07479732","phase":"PHASE1,PHASE2","title":"Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-03-05","conditions":["Osteosarcoma","Osteosarcoma Metastatic"],"enrollment":56,"completionDate":"2028-01-01"},{"nctId":"NCT07464756","phase":"PHASE2","title":"SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-04-05","conditions":["Gastric Adenocarcinoma"],"enrollment":80,"completionDate":"2030-07-31"},{"nctId":"NCT07463248","phase":"PHASE2","title":"PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Wang Xin","startDate":"2026-03-05","conditions":["Hepatocellular Carcinoma (HCC)"],"enrollment":64,"completionDate":"2029-01-31"},{"nctId":"NCT02867956","phase":"PHASE2","title":"Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2016-08-10","conditions":["Ovarian Cancer"],"enrollment":35,"completionDate":"2019-09-10"},{"nctId":"NCT06346392","phase":"PHASE3","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-03-04","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"enrollment":572,"completionDate":"2026-09-14"},{"nctId":"NCT03083041","phase":"PHASE2","title":"A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-03-13","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":210,"completionDate":"2022-04-22"},{"nctId":"NCT07033819","phase":"PHASE2","title":"Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-06-25","conditions":["Ovarian Cancer"],"enrollment":48,"completionDate":"2028-06-01"},{"nctId":"NCT03463876","phase":"PHASE2","title":"A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-03-08","conditions":["Hepatocellular Carcinoma"],"enrollment":190,"completionDate":"2021-03-10"},{"nctId":"NCT05451290","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-11-01","conditions":["Advanced Biliary Tract Carcinoma"],"enrollment":30,"completionDate":"2026-12-03"},{"nctId":"NCT05673824","phase":"PHASE2","title":"Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.","status":"COMPLETED","sponsor":"Fudan University","startDate":"2023-01-03","conditions":["Nephrotoxicity"],"enrollment":76,"completionDate":"2025-12-01"},{"nctId":"NCT06351020","phase":"PHASE3","title":"LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"LaNova Medicines Zhejiang Co., Ltd.","startDate":"2024-06-24","conditions":["Locally Advanced or Metastatic GC and GCJ Adenocarcinoma"],"enrollment":387,"completionDate":"2026-12-15"},{"nctId":"NCT05027386","phase":"PHASE1,PHASE2","title":"Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-08-26","conditions":["Neuroblastoma"],"enrollment":125,"completionDate":"2026-02-04"},{"nctId":"NCT05139095","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-01-27","conditions":["Gestational Trophoblastic Neoplasia"],"enrollment":70,"completionDate":"2027-01-01"},{"nctId":"NCT03092895","phase":"PHASE2","title":"A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-04-24","conditions":["Advanced Primary Liver Cancer","Advanced Biliary Tract Carcinoma"],"enrollment":157,"completionDate":"2021-03-31"},{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":["Metastatic Breast Cancer","HRD-Positive/HER2-Negative Advanced Breast Cancer"],"enrollment":200,"completionDate":"2031-03"},{"nctId":"NCT06693128","phase":"PHASE2","title":"Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-11-21","conditions":["Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma"],"enrollment":80,"completionDate":"2027-12-31"},{"nctId":"NCT07371871","phase":"NA","title":"A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2026-01-08","conditions":["Advanced Gastric Cancer"],"enrollment":30,"completionDate":"2028-12-31"},{"nctId":"NCT07363356","phase":"PHASE2","title":"Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2026-01-30","conditions":["Hepatocellular Carcinoma Resectable"],"enrollment":56,"completionDate":"2028-11-30"},{"nctId":"NCT04208347","phase":"PHASE2,PHASE3","title":"Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2019-12-18","conditions":["Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma"],"enrollment":580,"completionDate":"2027-12"},{"nctId":"NCT07357532","phase":"PHASE2","title":"Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-01-31","conditions":["Small Cell Lung Carcinoma"],"enrollment":44,"completionDate":"2028-10-30"},{"nctId":"NCT05198609","phase":"PHASE3","title":"Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-01-17","conditions":["Hepatocellular Carcinoma"],"enrollment":214,"completionDate":"2026-07-01"},{"nctId":"NCT04342910","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-21","conditions":["Gastric Cancer"],"enrollment":550,"completionDate":"2026-09-01"},{"nctId":"NCT07353684","phase":"PHASE2","title":"Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2025-05-11","conditions":["Adebrelimab","Adenocarcinoma of GE Junction","Adenocarcinoma of Stomach"],"enrollment":49,"completionDate":"2028-01-31"},{"nctId":"NCT07351513","phase":"PHASE2","title":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Eastern Hepatobiliary Surgery Hospital","startDate":"2026-01-30","conditions":["Unresectable Hepatocellular Carcinoma"],"enrollment":94,"completionDate":"2028-12-31"},{"nctId":"NCT07314372","phase":"PHASE2","title":"FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-02-01","conditions":["Unresectable Hepatocellular Carcinoma (HCC)","Hepatocellular Carcinoma (HCC)","Liver Cancer Adult"],"enrollment":86,"completionDate":"2028-12"},{"nctId":"NCT07334483","phase":"PHASE2","title":"A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC","status":"RECRUITING","sponsor":"GrandPharma (China) Co., Ltd.","startDate":"2025-08-22","conditions":["HCC"],"enrollment":120,"completionDate":"2027-12-30"},{"nctId":"NCT07333287","phase":"PHASE2","title":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.","status":"NOT_YET_RECRUITING","sponsor":"Shandong Provincial Hospital","startDate":"2026-02-01","conditions":["Pancreatic Cancer Liver Metastases","Immunotherapy-naive"],"enrollment":38,"completionDate":"2028-11-30"},{"nctId":"NCT07330271","phase":"NA","title":"PTC-Guided Therapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2025-12-02","conditions":["Peritoneal Mesothelioma"],"enrollment":347,"completionDate":"2031-11-01"},{"nctId":"NCT07324473","phase":"PHASE2","title":"Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2026-01-01","conditions":["Hepatocellular Carcinomas","Resistance to Immunotherapy","Immunomodulation","Drug Repurposing"],"enrollment":65,"completionDate":"2029-01-01"},{"nctId":"NCT07314203","phase":"PHASE3","title":"Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2026-12-25","conditions":["Gastric Cancer","Surgery"],"enrollment":118,"completionDate":"2028-08-25"},{"nctId":"NCT07311408","phase":"PHASE2","title":"SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure","status":"RECRUITING","sponsor":"Jingdong Zhang","startDate":"2026-01-01","conditions":["Gastric Cancer (GC)","Gastroesophageal Junction Adenocarcinoma"],"enrollment":40,"completionDate":"2029-12-01"},{"nctId":"NCT04639180","phase":"PHASE3","title":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-01","conditions":["Hepatocellular Carcinoma (HCC)"],"enrollment":687,"completionDate":"2026-07-31"},{"nctId":"NCT07309419","phase":"PHASE2,PHASE3","title":"A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-22","conditions":["Hepatocellular Carcinoma"],"enrollment":222,"completionDate":"2030-06-30"},{"nctId":"NCT07289997","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-09-28","conditions":["AFP Gastric or Gastroesophageal Junction Adenocarcinoma","PD-1/CTLA-4","AFPGC","Immunotherapy"],"enrollment":39,"completionDate":"2028-09"},{"nctId":"NCT07267806","phase":"PHASE3","title":"Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC","status":"RECRUITING","sponsor":"Linhui Peng","startDate":"2025-10-31","conditions":["Hepato Cellular Carcinoma (HCC)","Chemotherapy Effect"],"enrollment":326,"completionDate":"2032-10"},{"nctId":"NCT05320692","phase":"PHASE3","title":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-08-09","conditions":["Hepatocellular Carcinoma"],"enrollment":423,"completionDate":"2026-07-30"},{"nctId":"NCT05235100","phase":"PHASE2","title":"Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02）","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2021-09-01","conditions":["Sarcoma,Soft Tissue","Extremity","Trunk","Intensity-modulated Radiotherapy","Targetd Therapy","Major Wound Complications"],"enrollment":30,"completionDate":"2024-08-31"},{"nctId":"NCT06172205","phase":"PHASE3","title":"Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07-01","conditions":["BCLC Stage C Hepatocellular Carcinoma","Chemotherapy Effect"],"enrollment":262,"completionDate":"2029-07-31"},{"nctId":"NCT06576973","phase":"PHASE2","title":"Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-08","conditions":["Esophageal Squamous Cell Carcinoma","Neoadjuvant Treatment"],"enrollment":35,"completionDate":"2031-12"},{"nctId":"NCT07157969","phase":"PHASE2","title":"ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-02-19","conditions":["HCC - Hepatocellular Carcinoma"],"enrollment":300,"completionDate":"2027-06-30"},{"nctId":"NCT06925516","phase":"PHASE2","title":"A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-01-22","conditions":["Intrahepatic Cholangiocarcinoma (Icc)"],"enrollment":38,"completionDate":"2027-10-01"},{"nctId":"NCT07236528","phase":"PHASE2","title":"Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2025-11-30","conditions":["Mucosal Melanoma"],"enrollment":30,"completionDate":"2028-05-31"},{"nctId":"NCT06281886","phase":"PHASE2","title":"Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-12-01","conditions":["Esophageal Squamous Cell Carcinoma","Efficacy","Toxicity"],"enrollment":170,"completionDate":"2026-12-01"},{"nctId":"NCT05367687","phase":"PHASE2","title":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-09-01","conditions":["Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation"],"enrollment":251,"completionDate":"2024-11-15"},{"nctId":"NCT06349317","phase":"PHASE2","title":"Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT","status":"RECRUITING","sponsor":"Yongyi Zeng","startDate":"2024-04-22","conditions":["Hepatocellular Carcinoma"],"enrollment":33,"completionDate":"2026-06"},{"nctId":"NCT07192848","phase":"PHASE2","title":"Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy","status":"NOT_YET_RECRUITING","sponsor":"Song Peng","startDate":"2025-09","conditions":["Hepatocellular Carcinoma Non-resectable"],"enrollment":47,"completionDate":"2027-06"},{"nctId":"NCT03813784","phase":"PHASE3","title":"A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-03-07","conditions":["Gastric Cancer","GastroEsophageal Cancer"],"enrollment":885,"completionDate":"2023-06-07"},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":["Salivary Gland Carcinoma","Precision Therapy"],"enrollment":39,"completionDate":"2028-07-10"},{"nctId":"NCT05934331","phase":"PHASE2","title":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","status":"RECRUITING","sponsor":"LaNova Medicines Zhejiang Co., Ltd.","startDate":"2023-07-27","conditions":["Malignant Neoplasms of Digestive Organs"],"enrollment":276,"completionDate":"2028-07-01"},{"nctId":"NCT07156617","phase":"","title":"A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data","status":"NOT_YET_RECRUITING","sponsor":"Xuhua Duan","startDate":"2025-10-01","conditions":["Hepatocellular Carcinoma (HCC)"],"enrollment":2000,"completionDate":"2028-10-01"},{"nctId":"NCT07154082","phase":"PHASE2","title":"Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Wei Zhang","startDate":"2025-12-30","conditions":["Hepatocellular Carcinoma (HCC)"],"enrollment":27,"completionDate":"2028-07-31"},{"nctId":"NCT07147101","phase":"","title":"Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":["Advanced Hepatocellular Carcinoma (HCC)"],"enrollment":150,"completionDate":"2028-09-01"},{"nctId":"NCT07135544","phase":"PHASE2","title":"A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer","status":"RECRUITING","sponsor":"Yongjun Chen","startDate":"2025-08-14","conditions":["Biliary Tract Cancer","Biliary Tract Cancer (CCA)"],"enrollment":37,"completionDate":"2028-12-30"},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":["Breast Neoplasm","Breast Cancer","Breast Tumors","Triple-Negative Breast Cancer (TNBC)","HER2-positive Breast Cancer","HER2-negative Breast Cancer","Hormone Receptor Positive Tumor","Hormone Receptor Negative Tumor","Early-stage Breast Cancer","Locally Advanced Breast Cancer"],"enrollment":716,"completionDate":"2028-09"},{"nctId":"NCT07105748","phase":"PHASE2","title":"HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-08-15","conditions":["Mixed Hepatocellular-cholangiocarcinoma"],"enrollment":45,"completionDate":"2028-08-01"},{"nctId":"NCT06255392","phase":"PHASE3","title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":["Fludzoparib" and Anti-angiogenic","HRD-positive/HER2-negative Advanced Breast Cancer"],"enrollment":200,"completionDate":"2031-03"},{"nctId":"NCT03320629","phase":"PHASE2","title":"A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2017-11-01","conditions":["Refractory or Metastatic Esophageal Squamous Cell Carcinoma"],"enrollment":7,"completionDate":"2018-12-31"},{"nctId":"NCT05156970","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2021-06-24","conditions":["Recurrent Head and Neck Squamous Cell Carcinoma","Metastatic Head and Neck Squamous Cell Carcinoma"],"enrollment":81,"completionDate":"2025-06-24"},{"nctId":"NCT04560127","phase":"PHASE2","title":"Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2020-09-23","conditions":["Radioactive Iodine-refractory Differentiated Thyroid Cancer"],"enrollment":20,"completionDate":"2025-12-31"},{"nctId":"NCT03777124","phase":"PHASE2","title":"Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-11","conditions":["NSCLC Stage IV","KRAS Gene Mutation","PD-1 Antibody","Chemotherapy Effect"],"enrollment":25,"completionDate":"2023-06-29"},{"nctId":"NCT06893887","phase":"NA","title":"Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Nanjing Tianyinshan Hospital","startDate":"2025-05-22","conditions":["Hepatocellular Carcinoma(HCC)"],"enrollment":300,"completionDate":"2028-03-15"},{"nctId":"NCT06769425","phase":"PHASE1","title":"HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-05-07","conditions":["Recurrent Ovarian Cancer","HER2-negative","Advanced Breast Cancer","TNBC","Advanced Prostate Cancer","Advanced Gastric Cancer"],"enrollment":157,"completionDate":"2026-08-31"},{"nctId":"NCT07031154","phase":"PHASE2","title":"A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-06-30","conditions":["Non-Small Cell Lung Cancer","Adebrelimab","Apatinib"],"enrollment":43,"completionDate":"2027-02-01"},{"nctId":"NCT07026149","phase":"PHASE2","title":"Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-08","conditions":["Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma"],"enrollment":30,"completionDate":"2030-05-31"},{"nctId":"NCT04625803","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Colon Cancer","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2021-01-04","conditions":["Colon Cancer","Neoadjuvant Therapy"],"enrollment":64,"completionDate":"2023-09-30"},{"nctId":"NCT06973330","phase":"PHASE2","title":"Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-07","conditions":["AFP Gastric or Gastroesophageal Junction Adenocarcinoma"],"enrollment":40,"completionDate":"2027-05-01"},{"nctId":"NCT06913777","phase":"PHASE3","title":"Neoadjuvant SNF Precision Therapy Phase III","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-08","conditions":["Neoadjuvant Therapy"],"enrollment":404,"completionDate":"2027-04-15"},{"nctId":"NCT04581473","phase":"PHASE1,PHASE2","title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection","status":"ACTIVE_NOT_RECRUITING","sponsor":"CARsgen Therapeutics Co., Ltd.","startDate":"2020-10-23","conditions":["Gastric Adenocarcinoma","Pancreatic Cancer","Gastroesophageal Junction Adenocarcinoma"],"enrollment":192,"completionDate":"2038-06-30"},{"nctId":"NCT06831175","phase":"PHASE2","title":"Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-03-15","conditions":["Adrenal Cortical Carcinoma","Adrenal Cortical Cancer","Adrenal Cancer"],"enrollment":28,"completionDate":"2031-12-31"},{"nctId":"NCT07000344","phase":"NA","title":"A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-07-01","conditions":["Ovarian Cancer"],"enrollment":70,"completionDate":"2028-10-01"},{"nctId":"NCT06429696","phase":"PHASE2","title":"PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-07-14","conditions":["Small Cell Lung Cancer Extensive Stage"],"enrollment":40,"completionDate":"2026-04-30"},{"nctId":"NCT06280105","phase":"PHASE2","title":"A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib","status":"RECRUITING","sponsor":"Meng Chao Hepatobiliary Hospital of Fujian Medical University","startDate":"2024-03-31","conditions":["Hepatocellular Carcinoma"],"enrollment":40,"completionDate":"2027-03-31"},{"nctId":"NCT04666090","phase":"PHASE2","title":"Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-11-23","conditions":["Esophageal Squamous Cell Carcinoma","Neoadjuvant Therapy"],"enrollment":42,"completionDate":"2030-11"},{"nctId":"NCT06889688","phase":"PHASE3","title":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-04-01","conditions":["Breast Cancer Stage IV"],"enrollment":246,"completionDate":"2031-03-31"},{"nctId":"NCT04072042","phase":"PHASE2","title":"BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2019-10-30","conditions":["Sarcoma"],"enrollment":30,"completionDate":"2027-09-01"},{"nctId":"NCT05409482","phase":"","title":"A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Meng Chao Hepatobiliary Hospital of Fujian Medical University","startDate":"2022-08-20","conditions":["Hepatocellular Carcinoma"],"enrollment":300,"completionDate":"2026-03-01"},{"nctId":"NCT04521153","phase":"PHASE2,PHASE3","title":"Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-03-25","conditions":["Hepatocellular Carcinoma","Immunotherapy","Molecular Targeted Therapy"],"enrollment":294,"completionDate":"2026-03-01"},{"nctId":"NCT06925243","phase":"PHASE3","title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Zuoyi Jiao","startDate":"2025-04-15","conditions":["Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])","Neoadjuvant Therapy","Adjuvant Chemotherapy","pCR Rate","MPR","ORR,OS,PFS"],"enrollment":682,"completionDate":"2030-12-31"},{"nctId":"NCT06483282","phase":"PHASE2","title":"A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jin Ying","startDate":"2024-06-21","conditions":["Small Cell Lung Cancer Limited Stage"],"enrollment":38,"completionDate":"2026-12-31"},{"nctId":"NCT04195828","phase":"PHASE2","title":"Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Fujian Medical University","startDate":"2020-06-18","conditions":["Advanced Gastric Cancer"],"enrollment":106,"completionDate":"2025-03-24"},{"nctId":"NCT05713994","phase":"","title":"Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Ze-yang Ding, MD","startDate":"2020-05-19","conditions":["Hepatocellular Carcinoma Non-resectable"],"enrollment":300,"completionDate":"2025-12-30"},{"nctId":"NCT06881017","phase":"PHASE2","title":"Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-05-01","conditions":["Gastric Cancer","HER2 + Gastric Cancer","CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction","PD-L1 Positive"],"enrollment":140,"completionDate":"2029-11-01"},{"nctId":"NCT05223088","phase":"PHASE2","title":"Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2021-10-31","conditions":["Immunotherapy","Gastrict Cancer"],"enrollment":40,"completionDate":"2024-04-30"},{"nctId":"NCT05512481","phase":"PHASE2","title":"Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2022-09-13","conditions":["Melanoma","Acral Melanoma","Temozolomide","Apatinib","Camrelizumab","Neoadjuvant","Pathological Response"],"enrollment":60,"completionDate":"2026-12-31"},{"nctId":"NCT05192798","phase":"PHASE2","title":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Bengbu Medical University","startDate":"2022-01-14","conditions":["Triple-negative Breast Cancer"],"enrollment":128,"completionDate":"2025-12-01"},{"nctId":"NCT04517357","phase":"PHASE2","title":"A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-10-16","conditions":["Relapsed Ovarian Cancer"],"enrollment":100,"completionDate":"2024-11-01"},{"nctId":"NCT04863430","phase":"PHASE2","title":"Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach","status":"WITHDRAWN","sponsor":"Peking University","startDate":"2021-05-11","conditions":["Gastric Cancer"],"enrollment":0,"completionDate":"2023-07-06"},{"nctId":"NCT06823050","phase":"","title":"A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC","status":"NOT_YET_RECRUITING","sponsor":"Xuhua Duan","startDate":"2025-03-01","conditions":["Hepatocellular Carcinoma"],"enrollment":59,"completionDate":"2028-02-28"},{"nctId":"NCT06796803","phase":"PHASE2,PHASE3","title":"Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-02-20","conditions":["Potentially Resectable Hepatocellular Carcinoma"],"enrollment":398,"completionDate":"2030-02-28"},{"nctId":"NCT04869488","phase":"PHASE2","title":"A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-07-19","conditions":["Metastatic Castration Resistant Prostate Cancer"],"enrollment":93,"completionDate":"2023-02-14"},{"nctId":"NCT06792162","phase":"PHASE2","title":"PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-04-20","conditions":["Gastric Cancer"],"enrollment":20,"completionDate":"2027-04"},{"nctId":"NCT06786312","phase":"PHASE2","title":"A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-01-25","conditions":["Small Cell Lung Cancer Extensive Stage"],"enrollment":34,"completionDate":"2028-09-25"},{"nctId":"NCT06773156","phase":"PHASE2","title":"Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2024-11-01","conditions":["Limited-stage Small Cell Lung Cancer (LS-SCLC)"],"enrollment":37,"completionDate":"2030-08-01"},{"nctId":"NCT06771154","phase":"PHASE2","title":"Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-04-01","conditions":["Recurrent/Metastatic Endometrial Cancer"],"enrollment":140,"completionDate":"2029-04-01"},{"nctId":"NCT06308575","phase":"PHASE2","title":"A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-11-01","conditions":["Metastatic Olfactory Neuroblastoma","Recurrent Olfactory Neuroblastoma"],"enrollment":0,"completionDate":"2024-11-05"},{"nctId":"NCT06764368","phase":"PHASE2","title":"Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2025-01-01","conditions":["Neuroendocrine Tumors"],"enrollment":39,"completionDate":"2028-06-01"},{"nctId":"NCT06759090","phase":"PHASE2","title":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-01-15","conditions":["Metastatic Pancreatic Carcinoma"],"enrollment":43,"completionDate":"2028-06-15"},{"nctId":"NCT06480864","phase":"NA","title":"Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Yunpeng Liu","startDate":"2024-08-09","conditions":["Small Cell Lung Cancer"],"enrollment":38,"completionDate":"2026-08"},{"nctId":"NCT05613478","phase":"PHASE3","title":"Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-01-31","conditions":["Hepatocellular Carcinoma","Immunotherapy","Preoperative"],"enrollment":130,"completionDate":"2027-11-01"},{"nctId":"NCT06749730","phase":"PHASE2","title":"Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-04-01","conditions":["Unresectable Biliary Tract Carcinoma"],"enrollment":63,"completionDate":"2027-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"018934","UNII":"5S371K6132","INN_ID":"10596","UMLSCUI":"C2346836","chemblId":"CHEMBL3186534","ChEMBL_ID":"CHEMBL3186534","DRUGBANK_ID":"DB14765","PUBCHEM_CID":"11315474","IUPHAR_LIGAND_ID":"7648","MESH_SUPPLEMENTAL_RECORD_UI":"C553458"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Zhongda Hospital","relationship":"Current Owner"}],"publicationCount":1525,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026","pmid":"41884828","title":"The clinical trial landscape of osteosarcoma: integrating trial data, immunotherapeutic trends, and biomarker insights.","journal":"Frontiers in immunology"},{"date":"2026 Mar 22","pmid":"41865121","title":"Effects and molecular mechanism of inhibiting p53 signaling pathway by NSUN4 on the resistance to BCL-2 inhibitor for diffuse large B-cell lymphoma.","journal":"Clinical and experimental medicine"},{"date":"2026","pmid":"41858574","title":"An Injectable Photothermal Responsive Liposome Hydrogel Co-Loaded with Bufalin, Apatinib, and IR820 for Inhibiting Postoperative Recurrence of Colon Cancer.","journal":"International journal of nanomedicine"},{"date":"2026","pmid":"41836236","title":"A Bayesian network meta-analysis: evaluating the efficacy and safety of targeted therapies in metastatic or advanced radioiodine-refractory differentiated thyroid cancer.","journal":"Frontiers in oncology"},{"date":"2026 Mar 11","pmid":"41825755","title":"Apatinib inhibits CYP1A2-mediated melatonin metabolism: in vitro, in vivo and molecular docking studies.","journal":"Chemico-biological interactions"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Zhongda Hospital","companyId":"zhongda-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":149,"withResults":7},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:30:49.975969+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}